Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cyclacel Pharmaceuticals, Inc. (CYCC : NSDQ)

• Company Description    CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $0.32 Daily Weekly Monthly 20 Day Moving Average: 7,184,259 shares Shares Outstanding: 207.34 (millions) Market Capitalization: $65.95 (millions) Beta: 0.52 52 Week High: $3.08 52 Week Low: $0.17 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 40.13% 35.79% 12 Week 3.65% 11.39% Year To Date -15.40% -11.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 200 CONNELL DRIVE SUITE 1500 - BERKELEY HEIGHTS,NJ 07922 USA ph: 908-517-7330 fax: 866-271-3466 ir@cyclacel.com http://www.cyclacel.com

• General Corporate Information    Officers Doris Wong Sing Ee - Chief Executive Officer Kiu Cu Seng - Chief Financial Officer and Secretary Avraham Ben-Tzvi - Director Kwang Fock Chong - Director David Natan - Director Peer Information Cyclacel Pharmaceuticals, Inc. (CORR.) Cyclacel Pharmaceuticals, Inc. (RSPI) Cyclacel Pharmaceuticals, Inc. (CGXP) Cyclacel Pharmaceuticals, Inc. (BGEN) Cyclacel Pharmaceuticals, Inc. (GTBP) Cyclacel Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23254L801 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/24 Next Expected EPS Date: 05/13/25 Share - Related Items Shares Outstanding: 207.34 Most Recent Split Date: 12.00 (0.07:1) Beta: 0.52 Market Capitalization: $65.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 891.26 EPS Growth vs. Year Ago Period: 94.70% vs. Previous Quarter: -83.33% Sales Growth vs. Year Ago Period: -37.50% vs. Previous Quarter: 150.00% ROE 03/31/25 - - 12/31/24 - - 09/30/24 - - ROA 03/31/25 - - 12/31/24 - -188.17 09/30/24 - -188.23 Current Ratio 03/31/25 - - 12/31/24 - 0.59 09/30/24 - 0.77 Quick Ratio 03/31/25 - - 12/31/24 - 0.59 09/30/24 - 0.77 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - -18,150.00 Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - -18,150.00 Pre-Tax Margin 03/31/25 - - 12/31/24 - -27,893.02 09/30/24 - -21,390.54 Book Value 03/31/25 - - 12/31/24 - -0.25 09/30/24 - -0.45 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Capital 03/31/25 - - 12/31/24 - - 09/30/24 - -

Powered by Zacks Investment Research ©